CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
MB-CART2019.1 Dose level 1 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03870945
NCT03870945Phase 1Completed
CompareCT.gov

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant B-NHL

Miltenyi Biomedicine GmbH·interventional·Posted Mar 12, 2019·Updated May 28, 2025

In Brief

A Phase 1 clinical trial evaluating MB-CART2019.1 Dose level 1 and MB-CART2019.1 Dose level 2 for B-cell Non Hodgkin Lymphoma. Completed, enrolled 12 participants across 3 sites.

Detailed Summary

This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Non Hodgkin Lymphoma
CountriesGermany
CollaboratorsICON plc

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedMar 12, 2019
Enrollment StartFeb 25, 2019
Primary CompletionDec 17, 2020
Study CompletionMay 28, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.3 years ago

Interventions

MB-CART2019.1 Dose level 1biological

This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.

MB-CART2019.1 Dose level 2biological

This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL.